ArticleWorld journal of surgery2017
Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer.
Article in World journal of surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.BMC cancer · 2019Pooled it
- Prediction of lymph node metastasis in early colorectal cancer based on histologic images by artificial intelligence.Scientific reports · 2022Trial
- Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.Frontiers in bioengineering and biotechnology · 2026Review
- Search for Mutations Connected With Non-Response to Anti-EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours.Cancer medicine · 2025Article
- Unveiling the dynamics of circulating tumor cells in colorectal cancer: from biology to clinical applications.Frontiers in cell and developmental biology · 2024Review
- Identification of genes with high heterogeneity of expression as a predictor of different prognosis and therapeutic responses in colorectal cancer: a challenge and a strategy.Cancer cell international · 2022Article
- Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.Cancers · 2022Article
- The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses.Frontiers in genetics · 2022Article
- Improving the overall survival prognosis prediction accuracy: A 9-gene signature in CRC patients.Cancer medicine · 2021Article
- Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability.International journal of cancer · 2021Article
- Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?Frontiers in oncology · 2021Review
- Evaluation of the Impact of Intratumoral Heterogeneity of Esophageal Cancer on Pathological Diagnosis and P16 Methylation and the Representativity of Endoscopic Biopsy.Frontiers in oncology · 2021Article
- Precision Medicine for the Management of Therapy Refractory Colorectal Cancer.Journal of personalized medicine · 2020Article
- Intratumor heterogeneity: A new perspective on colorectal cancer research.Cancer medicine · 2020Review
- Identifying a ten-microRNA signature as a superior prognosis biomarker in colon adenocarcinoma.Cancer cell international · 2019Article
- Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?International journal of molecular sciences · 2018Review
- The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.Journal of cancer research and clinical oncology · 2018Article
- Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.Drug delivery and translational research · 2018Article
- Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionColorectal cancer (CRC) is a highly heterogeneous disease, with pathologically similar cancers having completely different responses to treatment and patient survival. Intra-tumour heterogeneity (defined as distinct morphological and phenotypic differences) has recently been demonstrated to be an important factor in the development and behaviour of cancer cells and can be used to determine response to anticancer therapy.
methodPatients with resected CRC had DNA extracted from eight defined tumour areas which were analysed for two genetic mutations (BRAF and KRAS) and one epigenetic trait (CpG island methylator phenotype/CIMP). Normal adjacent tissue was studied as control.
resultsTwelve patients with CRC were included. Intra-tumoural heterogeneity for KRAS mutation was seen in 2 patients (17%). There was no statistical evidence of CIMP status heterogeneity (p = 0.85), but 6 of the 12 patients (50%) demonstrated at least one heterogeneous area within the tumour. DISCUSSION: Intra-tumoural heterogeneity for both genetic and epigenetic factors in CRC is more prevalent than previously thought in Stage II and Stage III CRC. This study provides new insight into epigenetic heterogeneity of CRC and supports the development of a more targeted biopsy strategy to support expansion of personalised treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.